Last reviewed 2026-04-19 · How we verify

Crenezumab dose level 2

Genentech, Inc. · Phase 1 active Small molecule

Crenezumab dose level 2 is a Small molecule drug developed by Genentech, Inc.. It is currently in Phase 1 development.

At a glance

Generic name	Crenezumab dose level 2
Sponsor	Genentech, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Crenezumab dose level 2 CI brief — competitive landscape report
Crenezumab dose level 2 updates RSS · CI watch RSS
Genentech, Inc. portfolio CI

Frequently asked questions about Crenezumab dose level 2

What is Crenezumab dose level 2?

Crenezumab dose level 2 is a Small molecule drug developed by Genentech, Inc..

Who makes Crenezumab dose level 2?

Crenezumab dose level 2 is developed by Genentech, Inc. (see full Genentech, Inc. pipeline at /company/genentech-inc).

What development phase is Crenezumab dose level 2 in?

Crenezumab dose level 2 is in Phase 1.

Manufacturer: Genentech, Inc. — full pipeline
Compare: Crenezumab dose level 2 vs similar drugs
Pricing: Crenezumab dose level 2 cost, discount & access